anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study population will consist of patients undergoing elective neurosurgery with planned postoperative recovery of at least 24 hours in the intensive care unit or medium care unit. Leiden University Medical Center is a neurosurgical center in which a wide variety of surgeries including tumor resection in the posterior cranial fossa (including vestibular schwannoma) are performed. Clinical experience has shown that this cohort of patients are in general, hemodynamically the most stable patients and receive the least amount of interventions compared to other cohorts of patients in the intensive care unit and medium care unit. For these reasons, the cohort of elective neurosurgical patients would be ideal to investigate the reason of the increased between- and within-subject variability of mitochondrial oxygen tension in the intensive care unit and medium care unit setting.
BACKGROUND: A French intersociety consensus on behalf the Société Française de Médecine Vasculaire and the Société de Chirurgie Vasculaire et Endovasculaire was proposed in 2021 for the management of patients with lower extremity peripheral artery disease (LEAD). Recent studies have been published and an update of this consensus about the management of low-density lipoprotein cholesterol (LDLc) and hypertriglyceridemia was required.
METHODS: A steering committee of 12 vascular physicians and surgeons defined questions of interest about LDLc and hypertriglyceridemia management. A French expert panel voted the proposals. Consensus was considered to have been achieved if more than 80% of the responses corresponded to either "Agreement" or "Disagreement".
RESULTS: Among the 56 experts who were asked to participate, 46 (82%) accepted. After the first round of the Delphi procedure, the 4 proposals reached consensus. The following suggestions and recommendations were approved: 1. For LEAD patients treated by the highest tolerated statin dose ± ezetimibe and who have an LDLc ≥0.70 g/L, we recommend adding a proprotein convertase subtilisin/kexin type 9 inhibitor. 2. For LEAD patients treated by statin and who have elevated triglyceride level between ≥150 mg/dL and ≤500 mg/dL, we suggest adding Icosapent Ethyl. 3. Before adding Icosapent Ethyl in LEAD patients treated with statin, we suggest looking for symptoms that may suggest atrial fibrillation. 4. For LEAD patients treated by Icosapent Ethyl and who have symptoms that suggest atrial fibrillation, we recommend performing an electrocardiogram.
CONCLUSIONS: This update will help clinicians to improve LEAD patient management.
PURPOSE: To obtain new compds. useful for prevention and treatment of aches including rheumatic ache, and for peripheral arterial and cerebrovascular ischemic fits.  
     CONSTITUTION: The new compds. include a compd. expressed by formula I, its isomers, epimers, diastereoisomers, its pharmaceutically acceptable adduct salts having a base when B in formula I has a phenol type hydroxy group, and its pharmaceutically acceptable adduct salts having an acid when R 2  in the formula is amino. In formula I, R 1  is H, CO-NR 7 R 8  (wherein R 7 , R 8  are each H, a 3 to 8 C alkyl, etc., or R 7  and R 8  with N form a heterocyclic system); R 4  is expressed by formula II; A is CO, CH 2 , etc.; B is H, a lower alkyl, etc. In formula II, R 2  is a lower alkyl with substituents of H, one or more halogens, or with substituents NR 5 R 6  (R 5 , R 6  are each H, an aryl, etc.), when R 1  and R 2  form CO. The compd. is, for example, 3-methyl-6-(3,5-di-tertiary butyl-4-hydroxycynnamoyl)benzoselenazolinone. The compd. expressed by formula I is obtd., for example, by alkylating a compd. expressed by formula III with an alkylating agent in nitrogen and then allowing the product to react with a compd. expressed by BCOOH in the presence of a polyphosphoric acid. 
     COPYRIGHT: (C)1992,JPO
FIELD: medicine. SUBSTANCE: one should puncture a protruding cystic part. Cystic content should be aspirated. Cystic free walls are dissected. Then one should perform gradual - from periphery towards center - preparation with ultrasound destructor or forcing of glycerol solution along the border of cystic wall and parenchymatous bottom. Then one should enucleate all intraorganic part of cystic wall out of parenchymatous bottom. External draining of perhepatic space should be conducted. The present method enables to completely remove nonparasitic cyst out of the bottom by, thus, providing sufficient hemostasis. EFFECT: higher efficiency of therapy. 2 cl, 2 ex
Retinal ischemia and abnormal blood vessels growth are major determinants in the pathogenesisof retinopathy of prematurity (ROP) and proliferative diabetic retinopathy (DR). The present study used mice model of oxygen-induced retinopathy (OIR) to investigate the role of Fzd7 during initial vaso-obliteration (VO) and subsequent hypoxia-induced neovascularization (NV) phases. In particular, the inventors performed two blocking strategies: a monoclonal antibody (mAbFzd7) directed against Fzd7 and a soluble Fzd7 receptor (CRD domain). In vivo intravitreal microinjection of mAbFzd7 or CRD receptor in mice after 5 days of exposure to 75% oxygen (P12) resulted in a significant decrease of pathological neovascularization in the treated eye compared to the control eye. Collectively, the results established that Fzd7 acts as an important regulator of retinal neovascularization and offers a promising anti-angiogenic strategy for the treatment of ischemic retinopathies. Accordingly, the present invention relates to use of Fzd7 inhibitors for the treatment of retinal neovascularization.
The target population for the study will be children between the ages of 6 and 18 months at baseline living in small-scale farming households in Chipata District, Zambia. As part of a cluster-randomized trial titled "Food Constraints, Yield Uncertainty and 'Ganyu' Labor" funded by IZA-DFID (PI: G Fink), 3,100 farming households in approximately 180 rural villages in Eastern Province are currently enrolled in a two-year study, which aims at assessing the effect of food loan programs on agricultural productivity. The study described here uses the "Food Constraints" population as a sampling frame; all households enrolled in the "Food Constraints" program that have a child between 6 and 18 months are invited to participate in this add-on trial. We anticipate that there will be around 600 eligible households recruited for this study. Study duration is about 18 months. Selected households will be visited for study enrollment and a short baseline assessment in September 2014, at which time the two interventions will also be rolled out. Final impact of the interventions will be assessed one year later, in September 2015.
This randomized, controlled, double-blind, split-mouth clinical trial meets the criteria for designing a clinical study under the conditions of the SPIRIT Statement. The study was approved by the Committee for Ethics in Research (CEP) of the Universidad Católica del Uruguay. The participants who will be recruited are patients who are undergoing orthodontic treatment at the Orthodontic Clinic of the Specialization Course in Orthopedics and Orthodontics at the Catholic University of Uruguay in the city of Montevideo, Uruguay; those who require the installation of bands on the lower first permanent molars.

Any change or change will be reported and clarified to the CEP and informed in publications. A copy of the signed informed consent will be sent to the participant by email (completed in the TCLE). The project will be registered at www.clinicaltrial.gov There is no conflict of interest about any product used in the work and about any author involved in the studio. The data will be published and there will be no restriction on the inclusion of data for publication. All data will be available for your consultation, and all patients will have access to their medical records at any time they wish.
Patients receive paclitaxel as in arm I and oral placebo twice daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
On 12 patients, dry cupping will be performed by using a disposable manual cupping set including a hand suction pump and plastic cups of different sizes. These cups will be placed over the points GB 30, Huantiao, BL-28 Pangguangshu, BL-54 ZHIBIAN and EM-Yaoyan. After dry cupping session core stabilization exercises will be added.
BACKGROUND: Calcium deficiency in women is strongly linked to an increased risk of developing preeclampsia. Mitochondrial calcium ([Ca2+]m) homeostasis is essential to regulate vascular smooth muscle cell (VSMC) function. However, the role of [Ca2+]m in preeclampsia development remains largely unknown.
METHODS: To investigate this, human spiral arteries obtained from normotensive and preeclamptic women were collected for vascular function, RNA sequencing, and VSMC studies. N(ω)-nitro-L-arginine methyl ester-induced preeclampsia animal experiments were established to investigate the effects of intervening in [Ca2+]m to improve the outcome for preeclamptic mothers or their infants.
RESULTS: Our initial findings revealed compromised vessel function in spiral arteries derived from patients with preeclampsia, as evidenced by diminished vasoconstriction and vasodilation responses to angiotensin II and sodium nitroprusside, respectively. Moreover, the spiral artery VSMCs from patients with preeclampsia exhibited phenotypic transformation and proliferation associated with the disrupted regulatory mechanisms of [Ca2+]m uptake. Subsequent in vitro experiments employing gain- and loss-of-function approaches demonstrated that the mitochondrial Na+/Ca2+ exchanger played a role in promoting phenotypic switching and impaired mitochondrial functions in VSMCs. Furthermore, mtNCLX (mitochondrial Na+/Ca2+ exchanger) inhibitor CGP37157 significantly improved VSMC phenotypic changes and restored mitochondrial function in both patients with preeclampsia-derived VSMCs and the preeclampsia rat model.
CONCLUSIONS: This study provides comprehensive evidence supporting the disrupted regulatory mechanisms of [Ca2+]m uptake in VSMCs of spiral arteries of patients with preeclampsia and further elucidates its correlation with VSMC phenotypic switching and defective spiral artery remodeling. The findings suggest that targeting mtNCLX holds promise as a novel therapeutic approach for managing preeclampsia.
PURPOSE: The present study investigated school absence among 1,076 5-15 year-old children with neurodevelopmental conditions (intellectual disability and/or autism) approximately one year following the start of COVID-19 in the UK.
METHODS: Parents completed an online survey indicating whether their child was absent from school during May 2021 and the reason for each absence. Multi-variable regression models investigated child, family and school variables associated with absenteeism and types of absenteeism. Qualitative data were collected on barriers and facilitators of school attendance.
RESULTS: During May 2021, 32% of children presented with persistent absence (missing ≥ 10% of school). School refusal and absence due to ill-health were the most frequent types of absence, accounting for 37% and 22% of days missed, respectively. COVID-19 related absence accounted for just 11% of days missed. Child anxiety was associated with overall absenteeism and with days missed because of school refusal. Parent pandemic anxiety and child conduct problems were not associated with school absenteeism. Hyperactivity was associated with lower levels of absenteeism and school refusal but higher levels of school exclusion. A positive parent-teacher relationship was associated with lower levels of absenteeism, school refusal and exclusion. Child unmet need in school was the most frequently reported barrier to attendance while COVID-19 was one of the least frequently reported barriers.
CONCLUSION: COVID-19 had a limited impact on school attendance problems during this period. Findings highlighted the role of child mental health in different types of absence and the likely protective role of a positive parent-teacher relationship.
Patients who are applying bexarotene gel should not concurrently use products that contain DEET (N,N-diethyl-m-toluamide), a common component of insect repellent products. An animal toxicology study showed increased DEET toxicity when DEET was included as part of the formulation. 

No formal studies to evaluate drug interactions with bexarotene have been conducted. Bexarotene oxidative metabolites appear to be formed through cytochrome P450 3A4. 

On the basis of the metabolism of bexarotene by cytochrome P450 3A4, concomitant ketoconazole, itraconazole, erythromycin and grapefruit juice could increase bexarotene plasma concentrations. Similarly, based on data that gemfibrozil increases bexarotene concentrations following oral bexarotene administration, concomitant gemfibrozil could increase bexarotene plasma concentrations. However, due to the low systemic exposure to bexarotene after low to moderately intense gel regimens (see CLINICAL PHARMACOLOGY), increases that occur are unlikely to be of sufficient magnitude to result in adverse effects. 

No drug interaction data are available on concomitant administration of bexarotene gel and other CTCL therapies.
PROBLEM TO BE SOLVED: To provide a mastication type orthodontic appliance.SOLUTION: A mastication type orthodontic appliance comprises at least one reform unit being a rigid body. The reform unit is attached to an upper jaw or lower jaw dental arch during mastication time, and a shape of the reform unit is maintained without deformation when teeth are stored therein. At least one first recess tub is formed on the reform unit, and has a shape for providing a first space on the surrounding of a first tooth of the upper jaw or lower jaw dental arch. The first tooth is a tooth with positional abnormality which should be reformed, and the first space is configured so that, the first tooth can move in the first space during mastication. At least one relaxing member is formed in the first space, and transmits and relaxes force between the first tooth and the first recess tub. During mastication, under an action of articulation load, an orthodontic function of the device is actuated.SELECTED DRAWING: Figure 1
Compositions, methods, and systems for manufacturing articles, particularly containers and packaging materials, having a particle packed, highly inorganically filled, cellular matrix are disclosed. Suitable inorganically filled mixtures are prepared by mixing together a starch-based binder, a solvent, inorganic aggregates, and optimal admixtures, e.g., fibers, mold-releasing agents, rheology-modifying agents, plasticizers, coating materials, and dispersants, in the correct proportions to form an article which has the desired performance criteria. The inorganically filled mixtures have a predetermined viscosity and are heated between molds at an elevated temperature and pressure to produce form-stable articles having a desired shape and a selectively controlled cellular, structure matrix. The molded articles may be placed in a high humidity chamber to obtain the necessary flexibility for their intended use. The articles may be manufactured to have properties substantially similar to articles presently made from conventional materials like paper, paperboard, polystyrene, plastic, or other organic materials. They have especial utility in the mass-production of containers, particularly food and beverage containers.
Methods and compositions are provided for the treatment of immune system-mediated diseases. The compositions of the invention have the property of reducing the expression of CD28 in cells of interest so as to moderate the pathogenic effects on the immune system in an immune system-mediated disease. The compositions of the invention include one or more different oligomers capable of reducing the expression of CD28. One aspect of the invention provides oligomers capable of reducing the expression of CD28 by interfering with its expression. The oligomers may be DNA, RNA, or various analogs thereof, and may include 14-50 base phosphorothioates having at least two sequences of GGGG separated by 3 to 5 bases. Other aspects of the invention provide genetic engineering vectors for the intracellular expression of oligomers of the invention in cells of interest, and formulations comprising one or more different oligomers of the invention. The formulations may be adapted for various forms of administration to the body or administration to cells to be reintroduced into the body. The methods of the invention involve modulating CD28 expression through the use of the oligomers of the invention. The methods may be used to treat immune system-mediated diseases and include methods of treating autoimmune disease, methods of reducing an inflammation response, methods of reducing the production of selected cytokines, methods of inactivating T cells, and methods of immunosuppressing a transplant patient.
The invention relates to a South China Sea conus striatus toxin gene and polypeptide S4.3 coded by the same, a preparation method for the polypeptide and application thereof. The A-superfamily conotoxin gene is obtained by cloning from a conus striatus tube by a method for constructing a cDNA library, and the DNA sequence of the gene is expressed as a (400)1 sequence in a sequence table. The amino acid sequence of the polypeptide S4.3 coded by the gene is expressed as a sequence table (400)2. The preparation method for the polypeptide constructs a recombinant expression vector pTRX-S4.3, and probes and optimizes the culture method and conditions so as to improve the expression quantity of the polypeptide S4.3. The preparation method for the polypeptide S4.3 can be used for improving the conventional polypeptide production method. The polypeptide S4.3 can promote quick growth of cells, and can be used for preparing medicaments for promoting the growth of the cells.
This is an in-clinic, single arm, open-label study assessing tachyphylaxis, tolerance, and withdrawal following repeated doses of Igalmi in adult males and females (18 to 65 years old, inclusive) with agitation associated with schizophrenia or bipolar disorder. Subjects will be screened for eligibility within 15 days of first dose and no study procedures will occur unless subjects provide written informed consent. Subjects will receive single doses of 180 μg of Igalmi as needed for the treatment of agitation over a period of 7 days followed by a 3- day follow-up period during which time no Igalmi will be administered in an effort to characterize any potential withdrawal. Subjects will sublingually self-administer Igalmi for an agitation episode that reaches a pre-dose PEC total score of 14 or greater, as determined by a trained rater. Safety assessments will be conducted before and after each dose. If the subject's agitation is recurrent or persistent, repeat doses of 90 µg may be administered (no more than 2 repeat doses within a 24-hour period) in the absence of any safety concerns or adverse events.
All subjects will initially receive baricitinib 2mg daily for 8 weeks. If no unexpected serious adverse events related to baricitinib have occurred during the first 8 weeks of treatment in the opinion of the investigator, the dose will be increased to 4 mg daily for 16 weeks.
He did not receive treatment after 4 weeks of intensive care. it functions only as a control group.
A system and method non-invasive biomedical optical imaging and spectroscopy with low-level light is described. The technique consists of a modulated light source (120) coupled to tissue (100) of a patient to introduce excitation light. Fluorescent light emitted in response to the excitation light is detected with sensor (148). The AC intensity and phase of the excitation and detected fluorescent light is provided to a processor (160) operatively coupled to sensor (148). Processor (160) employs the measured re-emission kinetics of excitation and fluorescent light to "map" the spatial variation of one or more fluorescence characteristics of the tissue (100). The fluorescence characteristic may be provided by exogenous contract agents, endogenous fluorophores, or both. The variations is determined by solving frequency domain diffusion equations at a number of designated points in the tissue as part of a recursive estimation algorithm. Processor (160) generates an imaging signal in accordance with the spatial variation of the fluorescence characteristic for provision to an output device (164). The output device (164) displays an image corresponding spatial variation of the fluorescence characteristic which corresponds to tissue (100) to aid in the detection and diagnosis of disease.
PURPOSE:To obtain an immunoactivating agent for person infected by virus of acquired immune deficiency syndrome, containing the Chinese medicine SHOSAIKOTO (blend of Bupleuri radix, etc. with other ingredients) and having extremely low toxicity and high safeness. CONSTITUTION:A diluting agent, auxiliary agent, etc., used in a conventional formulation is added to a dried extract powder of SHOSAIKOTO (a Chinese medicine produced from blend of Bupleuri radix with the following ingredients) produced according to blend ratio of crude drugs described in old books such as SHOKANRON and KINKIYORYAKU, and formulated by a conventional method to provide the aimed agent. The agent can be prepared in a form such as inhalant, granule, tablet, capsule agent, etc., and administered in dose of 1-10g / day / head three times as an amount of dried extract powder. A blend ratio of each crude medicine of the above-mentioned BHOSAIKOTO is illus trated by 4-7pts.wt. Bupleuri Radix, 3pts.wt. Scutellariae Radix, 2pts.wt. Glycyrrhizac Radix, 2-3pts.wt. Ginseng Radix, 1pt.wt. Zingiberis, 2-3pts.wt. Zizyphi Fructus and 4-5pts.wt. Pinelliae Tuber.
FIELD: medicine. SUBSTANCE: the present innovation deals with selective marking mitochondria of cancer cells due to delivering cationic supravital mitochondrial marking agent towards epithelial cancer cells. Agent, also, may include the reaction product of marking agent and preparation for cancer chemotherapy or be in the mixture with it. The present innovation helps to detect and selectively eliminate cancer cells at the presence of normal ones. EFFECT: higher efficiency of the technique suggested. 10 cl, 9 ex